Section: Faculty & Research
Milton Brown
Title
Director, Drug Discovery Program
Edwin H. Richard and Elisabeth Richard von Matsch Endowed Chair in Experimental Therapeutics
Edwin H. Richard and Elisabeth Richard von Matsch Endowed Chair in Experimental Therapeutics
Department
LOMBARDI COMPREHENSIVE CANCER CENTER
General profile
Phone
202-687-8605
Location
EP07 Research Building
Bio
In addition to his research and academic responsibilities at GUMC, Dr. Milton Brown has established the Drug Discovery Program (DDP) at the Georgetown University Medical Center, which supports more than 20 investigators in drug discovery and development.
On Thursday, January 17, 2008, Dr. Brown was recognized as the inaugural Edwin H. Richard and Elisabeth Richard von Matsch Endowed Chair in Experimental Therapeutics at Georgetown. As chair, Dr. Brown continues to lead Georgetown’s thriving Drug Discovery Program in its mission to develop lifesaving diagnostics and therapeutics.
Dr. Brown is an experienced leader in establishing Academic drug discovery centers and has more than 15 years of experience in developing new drugs in the fields of cancer and neuroscience. His has positioned the DDP at the interface of chemistry and medicine to help facilitate the translation of basic science into new medical therapies. Under Dr. Brown's leadership, the DDP was selected as a Chemical Diversity Center in the National Cancer Institute's Chemical Biology Program.
At the Medical Center, Dr. Brown has taken more than a dozen projects from concept through preclinical studies in several therapeutic areas.
His laboratory is equipped to design and synthesize new compounds, evaluate the compounds against targeted proteins and human cancer cell lines, characterize the maximal tolerated dose (MTD) in small animals and to evaluate candidate compounds in mouse xenograft models.
Dr. Brown served as a member of both the Experimental Therapeutics and the Drug Discovery and Molecular Pharmacology study sections at NIH (2001-2006) and in the 2006 Breast Cancer Experimental Therapeutics study section at the Department of Defense (DOD). He also served for two years as an elected member of the medicinal chemistry long-range planning committee for the American Chemical Society.
Br. Brown has a very unique educational background, having earned his PhD in synthetic chemistry from University of Alabama at Birmingham in 1995, and his medical degree (M.D.) at the University of Virginia in 1999. Dr. Brown received postdoctoral training in the Department of Chemistry at UVA, and in 2000 became an assistant professor of chemistry in that department.
Dr. Brown is a reviewer for the Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry and the European Journal of Medicinal Chemistry. Dr. Brown has given more than 80 invited lectures in the United States, Europe and China on drug discovery and development topics. Dr. Brown is presently a consultant with several biotech companies and one major pharmaceutical company in the area of medicinal chemistry and drug discovery.
On Thursday, January 17, 2008, Dr. Brown was recognized as the inaugural Edwin H. Richard and Elisabeth Richard von Matsch Endowed Chair in Experimental Therapeutics at Georgetown. As chair, Dr. Brown continues to lead Georgetown’s thriving Drug Discovery Program in its mission to develop lifesaving diagnostics and therapeutics.
Dr. Brown is an experienced leader in establishing Academic drug discovery centers and has more than 15 years of experience in developing new drugs in the fields of cancer and neuroscience. His has positioned the DDP at the interface of chemistry and medicine to help facilitate the translation of basic science into new medical therapies. Under Dr. Brown's leadership, the DDP was selected as a Chemical Diversity Center in the National Cancer Institute's Chemical Biology Program.
At the Medical Center, Dr. Brown has taken more than a dozen projects from concept through preclinical studies in several therapeutic areas.
His laboratory is equipped to design and synthesize new compounds, evaluate the compounds against targeted proteins and human cancer cell lines, characterize the maximal tolerated dose (MTD) in small animals and to evaluate candidate compounds in mouse xenograft models.
Dr. Brown served as a member of both the Experimental Therapeutics and the Drug Discovery and Molecular Pharmacology study sections at NIH (2001-2006) and in the 2006 Breast Cancer Experimental Therapeutics study section at the Department of Defense (DOD). He also served for two years as an elected member of the medicinal chemistry long-range planning committee for the American Chemical Society.
Br. Brown has a very unique educational background, having earned his PhD in synthetic chemistry from University of Alabama at Birmingham in 1995, and his medical degree (M.D.) at the University of Virginia in 1999. Dr. Brown received postdoctoral training in the Department of Chemistry at UVA, and in 2000 became an assistant professor of chemistry in that department.
Dr. Brown is a reviewer for the Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry and the European Journal of Medicinal Chemistry. Dr. Brown has given more than 80 invited lectures in the United States, Europe and China on drug discovery and development topics. Dr. Brown is presently a consultant with several biotech companies and one major pharmaceutical company in the area of medicinal chemistry and drug discovery.
Education
- M.D. (1999) University of Virginia,
- Ph.D (1995) University of Alabama at Birmingham, Organic Chemistry
- B. S. (1987) Oakwood University, Biology